Acute coronary syndrome (ACS) patients who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor 1 month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding, with no increased risk of clotting-related adverse events, at 12 months compared with patients who continued dual antiplatelet therapy (DAPT) for a full year, report the principal findings from the ULTIMATE-DAPT trial.